Bryan Poltilove on Evolving Bioprocessing Manufacturing Paradigms

Bryan Poltilove, a strategic advisor and independent board director with over two decades of experience in bioprocessing and advanced therapy manufacturing, shares his perspective on how the industry is shifting in Part 1 of a two-part interview with PharmTech at INTERPHEX 2026.

Poltilove emphasizes that while GMP manufacturing and validation remain non-negotiable table stakes, the broader manufacturing landscape is undergoing a significant transformation. He draws a parallel to the automotive industry's shift toward just-in-time production in the 1980s, arguing that biopharma is undergoing a similar paradigm shift, moving away from large, centralized inventory models toward more flexible, distributed approaches.

Key to this evolution is the growth of point-of-care and place-of-care manufacturing, particularly in cell therapy, where modular clean rooms and specialized cell processing technologies are enabling production at hospital settings. Poltilove stresses that this shift must not come at the expense of reproducibility, quality standards, or regulatory compliance. The challenge lies in achieving greater logistical flexibility while preserving those fundamentals.

As a concrete example of innovation in this space, Poltilove highlights Nucleus Biologics, whose approach to cell culture media manufacturing he describes as a "Nespresso/Keurig-type model,” enabling on-demand, point-of-care reagent production rather than reliance on large pre-made lots. Having spent nearly 20 years in the cell culture media space, including leading portfolios of Thermo Fisher’s Gibco products for more than a decade, Poltilove called the Nucleus Biologics technology one of the most potentially revolutionary he has encountered throughout his career.